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Two large clustered-randomized trials have proven 
that ClearGuard® caps can reduce CRBSI by 56-69% 
(Hymes et al., 2017; Brunelli et al., 2018). 
Purpose Statement
The aim of this project was reducing CRBSI’s below 
the predicted number of bloodstream infections with 
the implementation of the ClearGuard® chlorhexidine-
based antimicrobial disinfecting cap. 
Evidence-Based Practice Change
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In the 13 months of the 
Brunelli et al., (2018) 
study, BSI rates 
decreased significantly 
with the use of the 
ClearGurad® caps 
(0.28 versus 0.75 PBCs 
per 1000 CVC-days
Using the ClearGuard® caps were associate with 
a 56% decreased rate of BSI when compared to 
the use of standard caps. During the last 6 months 
of the study, use of the ClearGuard® caps were 
associated with a 69% lower BSI (Hymes et al., 
2017). SUSTAINED USE = BETTER OUTCOMES
respectively; P=0.001) 
ClearGuard® caps can reduce CRBSI by 56-69%
Currently use: Tego® connector. 
Research of a 70% isopropyl 
disinfecting cap placed over the 
Tego® connector not as superior 
compared to the ClearGuard® 
cap
ClearGuard® cap uses a dry form of 
chlorhexidine antimicrobial disinfectant. The 
cap is placed on the ends of the hemodialysis 
catheter at the end of each treatment and 
remains in place between treatments to provide 
continuous disinfection.
Pre-implementation audits (prior 3 months)
206 patients, 49 patients with a tunneled 
catheter and 2 access related BSI’s. 
1 BSI was attributed to a fistula, 
And 1 BSI was attributed to a graft. 
0 BSI’s were attributed to a catheter.
Results were not unexpected….EXTENDED use of the ClearGuard® cap proves 
to decrease CRBSI by 56-69% The Hymes (2017) study showed the last 6 
months of use: infection rates of 0.18 (3rd qtr.) and 0.26/1000 CVC days (4th qtr.) 
compared to the first six months at 0.33/1000 days for both the 1st and 
2nd quarter. Limitations encountered were time and a small sample size. A three-
month time frame did not allow enough time to adequately assess for 
improvement of CRBSI’s and using one single hemodialysis unit and not all 12 
outpatient units associated with this organization was also another limitation. 
Using more dialysis units would have given a much larger sample size. After completion of my project, based on all data 
available, the senior organization of this project 
unit decided to implement the ClearGuard® cap 
throughout their entire hemodialysis population 
This includes12 hemodialysis units, totaling 405 
patients, with 119 catheters within their 
organization. 
Post-implementation audits (my project-3 months) 
186 patients,  54 patients with a tunneled 
catheter.
0 BSI’s were attributed to a fistula, graft, 
or catheter during this time period 
(Table 2).
Reduction of CRBSI will have beneficial impacts on healthcare organizations and this patient population
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